Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: While primary aldosteronism (PA) is typically screened in hypertensive patients, normotensive PA remains underrecognized, especially in complex cases where standard diagnostic approaches fail. We present a challenging case of normotensive PA complicated by myasthenia gravis (MG) requiring chronic glucocorticoids, which interfere with conventional cortisol-based adrenal venous sampling (AVS) interpretation. This case highlights the pivotal role of Ga-pentixafor PET/CT as an innovative alternative for subtype differentiation in such complex scenarios.

Methods: A 30-year-old normotensive woman with MG (on long-term glucocorticoids) was incidentally found to have a left adrenal adenoma. Biochemical testing confirmed PA (elevated ARR, positive captopril challenge test and saline infusion test). Due to glucocorticoid interference with AVS interpretation, Ga-pentixafor PET/CT was utilized for precise localization. We further reviewed literature on alternative diagnostic strategies for PA when conventional cortisol-based AVS interpretation is compromised.

Results: Ga-pentixafor PET/CT successfully localized the aldosterone-producing adenoma, guiding laparoscopic adrenalectomy. Postoperatively, the patient achieved complete biochemical remission (normalized ARR and potassium). To our knowledge, this is the first reported use of Ga-pentixafor PET/CT for PA subtype diagnosis in a glucocorticoid-dependent normotensive patient, offering a paradigm for similar challenging cases.

Conclusions: For PA patients with confounding factors affecting cortisol-based AVS interpretation (e.g., chronic glucocorticoid use), Ga-pentixafor PET/CT emerges as a robust non-invasive alternative for accurate subtype differentiation. This case provides a novel diagnostic framework for complex PA presentations, advocating for tailored imaging strategies to overcome traditional limitations.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-025-04311-xDOI Listing

Publication Analysis

Top Keywords

ga-pentixafor pet/ct
24
avs interpretation
16
primary aldosteronism
8
myasthenia gravis
8
conventional cortisol-based
8
subtype differentiation
8
cortisol-based avs
8
ga-pentixafor
6
pet/ct
6
normotensive
5

Similar Publications

Background: For patients diagnosed with primary aldosteronism (PA) accompanied by bilateral adrenal lesions, identifying optimal candidates for surgical intervention remains a significant clinical challenge. Although adrenal venous sampling (AVS) is currently the gold standard for lateralizing aldosterone hypersecretion, its technical complexity, invasiveness, and interpretive difficulties restrict its widespread adoption. In this study, we aimed to investigate the clinical application of Ga-pentixafor positron emission tomography/computed tomography (PET/CT) as a non-invasive imaging modality in AVS-free surgical decision-making for PA patients with bilateral adrenal lesions.

View Article and Find Full Text PDF

The C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a critical molecular imaging target in various malignancies due to its central role in tumor progression, metastasis, and resistance to therapy. Among the imaging modalities developed to exploit this target, [68Ga]Ga-Pentixafor-a positron emission tomography (PET) radiopharmaceutical-has shown potential in diagnostic imaging. However, its diagnostic utility in solid tumors remains relatively underexplored, particularly in comparison to the widely utilized [18F]fluorodeoxyglucose ([18F]FDG) PET/CT.

View Article and Find Full Text PDF

The utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas.

Eur J Nucl Med Mol Imaging

August 2025

Department of Cardiology, Binhai Campus of the First Affiliated Hospital, National Regional Medical Center, Fujian Medical University, Fuzhou, People's Republic of China.

Purpose: Expression of CXC chemokine receptor 4 (CXCR4) has proved to be a valuable tool for guiding the diagnosis and treatment of aldosterone-producing adenoma (APA). In this study, we evaluated whether CXCR4 imaging with Ga-pentixafor PET/CT shows significant changes after superselective adrenal artery embolization (SAAE).

Methods: We prospectively recruited 25 patients with clinically diagnosed APA.

View Article and Find Full Text PDF

Objective: Gallium-68 (Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.

Materials And Methods: Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice.

View Article and Find Full Text PDF

Background: We aim to investigate the prognostic value of [Ga]Ga-Pentixafor PET/CT in multiple myeloma (MM) patients.

Results: This is a retrospective analysis of a prospective cohort study. Twenty-five patients with treatment-naïve, newly diagnosed MM were included.

View Article and Find Full Text PDF